Clinical Trials
22 trialsNCT00812669 2025-07-08
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
Cancer Trials Ireland
Phase 2 Completed
NCT00410956 2024-12-10
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00520767 2023-12-22
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00611351 2023-10-23
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Phase 2 Completed
NCT01261247 2022-05-24
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 2 Completed
NCT01328535 2020-10-22
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT00509093 2020-03-17
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00514215 2020-03-05
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00513695 2019-08-07
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
Phase 2 Completed
NCT01093586 2019-01-23
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00425477 2018-10-05
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00847171 2018-09-26
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01682044 2017-10-09
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
Roswell Park Cancer Institute
Phase 2 Completed
NCT01110135 2017-05-24
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Phase 2 Completed
NCT00041028 2015-05-01
EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00049140 2014-07-25
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer
Duke University
Phase 2 Completed
NCT00458523 2013-08-12
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
National Cancer Institute (NCI)
Phase 2 Completed
NCT01158534 2012-08-07
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00616720 2011-05-16
Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT00618345 2011-05-16
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT00652860 2011-05-16
Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT00410657 2010-05-14
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed